Early divergence of treatment response trajectories to adalimumab or its biosimilar in active ankylosing spondylitis: consensus clustering analysis of a randomized controlled trial - Quiz - MDSpire

Early divergence of treatment response trajectories to adalimumab or its biosimilar in active ankylosing spondylitis: consensus clustering analysis of a randomized controlled trial

  • By

  • Zhiqiang Zhong

  • Hongjuan Lu

  • Ting Li

  • Lingying Ye

  • Ling Zhou

  • Xiaobing Wang

  • Xin Wu

  • Huji Xu

  • June 23, 2026

  • 0 min

Share

Original Source(s)

Early divergence of treatment response trajectories to adalimumab or its biosimilar in active ankylosing spondylitis: consensus clustering analysis of a randomized controlled trial

  • by Zhiqiang Zhong, Hongjuan Lu, Ting Li, Lingying Ye, Ling Zhou, Xiaobing Wang, Xin Wu, Huji Xu

  • June 23, 2026

Related Content

Potential association between IL-17A inhibition and blood pressure reduction in patients with axial spondyloarthritis

Labial-gland artificial intelligence model screening for autoimmune thyroiditis among patients with connective tissue disease

Distinct IgM and IgG autoantibody profiles characterize incomplete and classified systemic autoimmune diseases